Latest News about ACLX
Recent news which mentions ACLX
Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday
April 02, 2025
From Benzinga
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
February 12, 2025
From Benzinga
In-Depth Examination Of 14 Analyst Recommendations For Arcellx
December 09, 2024
Tickers
ACLX
From Benzinga
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
December 09, 2024
From Benzinga
From Benzinga
Cracking The Code: Understanding Analyst Reviews For Arcellx
October 22, 2024
Tickers
ACLX
From Benzinga
Tickers
ACLX
From InvestorPlace
From InvestorPlace
7 Biotech Stocks to Put on Your Breakthrough Radar
May 27, 2024
Tags
Stocks to Buy
NYSE:NVO,NYSE:ABBV,NASDAQ:CRSP,NASDAQ:BBIO,NASDAQ:ACLX,NASDAQ:GILD,NASDAQ:COYA,NASDAQ:AGEN
GILD
From InvestorPlace
Tickers
ACLX
From InvestorPlace
From InvestorPlace
From Benzinga
Arcellx Analysts Boost Their Forecasts After Q4 Results
February 29, 2024
From Benzinga
The 3 Biotech Stocks That Could Make Your February Unforgettable
February 15, 2024
Tags
Market News
NVS
NASDAQ:VKTX,NYSE:ADCT,NASDAQ:ACLX,NYSE:JNJ,NYSE:PFE,NASDAQ:AMAM,NASDAQ:SNY,NYSE:NVS
From InvestorPlace
From InvestorPlace
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
January 04, 2024
From Benzinga
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
December 15, 2023
From InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free